Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)

Summary

This is a Phase I, FIH, open-label, dose escalation study evaluating Safety and Efficacy of UCART targeting CS1 in patients with Relapsed or Refractory Multiple Myeloma (MM). The purpose of this study is to evaluate the safety and clinical activity of UCARTCS1A and to determine the Maximum Tolerated Dose (MTD).

Timeline

Start

2019-11-21

Primary completion

2023-06-18

Completion

2023-06-18

Outcome

Outcome not reported

Stopped: “The trial was discontinued due to sponsor's decision and not a consequence of any safety concern.”

Drugs

Indications